Ixico Share News (IXI)

Thursday broker round-up UPDATE

Antofagasta: Deutsche Bank cuts target price from 770p to 735p and downgrades to sell. Investec cuts target price from 753p to 726p keeping its sell recommendation. Ashmore Group: HSBC Holdings lowers target price from 410p to 400p retaining its overweight rating. Avacta Group: Numis shifts target

Standard Chartered non-exec builds company holding after profit decline

An Independent Non-Executive Director of Standard Chartered has this week upped his stake in the group by a quarter with the purchase of 2,500 shares. John Paynter, who was appointed to his role in 2008, bought the shares at 1,246.50p each for a total of £31,163, taking his total holding to 12,50

DIRECTOR DEALINGS: Ixico Non-Executives Buy Shares

LONDON (Alliance News) - Ixico PLC said Tuesday that non-executive chairman Andy Richards had bought 13,700 shares at 78 pence each. Non-executive director Tim Sharpington bought 12,750 shares at 78.5 pence also on Tuesday. Following these purchases Richards has a 0.2% interest in the

IXICO, VirtualScopics In International Commercial, Operational Alliance

LONDON (Alliance News) - Brain health company IXICO PLC Friday said it has entered into an international commercial and operational alliance with VirtualScopics Inc, a quantitative medical imaging provider. "The proposed alliance will provide the clinical trials industry with global operati

IXICO Positive On Position Following Business Transition

LONDON (Alliance News) - IXICO PLC, the company formed when IXICO Ltd and Phytopharm PLC merged, said Friday that it believes it is strongly positioned in its core clinical trials and experimental medicine markets following the transition of its business. The company formally known as Phyto

DIRECTOR DEALINGS: IXICO Non-Executive Director Buys Shares

IXICO Non-Executive Director Buys Shares

DIRECTOR DEALINGS: Ixico Executive Buys Shares

DIRECTOR DEALINGS: IXICO CEO Buys 4,000 Shares

DIRECTOR DEALINGS: IXICO Chairman Buys Shares